Vicus Therapeutics

Vicus Therapeutics is an immuno-oncology company. Vicus employs a rational, data-driven discovery process to repurpose FDA-approved drugs into precision medicines that suppress pro-inflammatory tumors, restore immune surveillance, and enhance treatment tolerance. Its products are at the forefront of two converging trends in the oncology market: the emergence of immunotherapy for cancer treatment and the shift towards precision medicine—delivering the right drug, at the right dose, to the right patient at the right time. Vicus's leading drug, VT-122, is the first multi-pathway neuroimmunomodulator for cancer treatment.